Physician profile
Mark Robert Keaton
NPI 1477530533
$26,425.33
in general payments reported to CMS, 2019-2025
38 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,477 · 2020: $4,861 · 2021: $1,943 · 2022: $3,463 · 2023: $325 · 2024: $9,432 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,165 · Travel and Lodging: $1,080 · Food and Beverage: $237 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,165.00 |
| Travel and Lodging | $1,080.26 |
| Food and Beverage | $236.68 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13,424.85 | 2019-2024 | Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $4,455.28 | 2020 | |
| Daiichi Sankyo INC. | $1,950.00 | 2022-2025 | Vanflyta |
| Heron Therapeutics, INC. | $1,923.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,090.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $444.25 | 2019-2023 | Keytruda, Lenvima |
| Amgen INC. | $329.29 | 2019-2020 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $214.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $200.00 | 2022 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Janssen Biotech, INC. | $186.94 | 2019-2023 | Erleada |
| Genzyme Corporation | $168.25 | 2019 | |
| Astellas Pharma US INC | $160.97 | 2019-2020 | |
| Puma Biotechnology, INC. | $135.95 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $135.27 | 2019-2020 | |
| Genentech USA, INC. | $133.11 | 2019-2020 | |
| Eisai INC. | $103.79 | 2019-2023 | |
| Pfizer INC. | $86.96 | 2019-2020 | |
| Celgene Corporation | $86.67 | 2019 | |
| Tesaro, INC. | $78.65 | 2019 | |
| Incyte Corporation | $73.18 | 2019-2020 | |
| Seagen INC. | $73.00 | 2019 | |
| Lilly USA, LLC | $55.49 | 2019-2023 | Retevmo, Verzenio, Jaypirca |
| Kyowa Kirin, INC. | $51.77 | 2019-2020 | |
| Gilead Sciences, INC. | $50.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.86 | 2019 | |
| Taiho Oncology, INC. | $43.47 | 2019-2020 | |
| Abbvie INC. | $41.88 | 2019 | |
| Tersera Therapeutics LLC | $33.66 | 2019 | |
| Kite Pharma, INC. | $32.05 | 2020-2024 | Yescarta |
| Exelixis INC. | $30.63 | 2019-2023 | Cabometyx |
| Emd Serono, INC. | $26.11 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.77 | 2019 | |
| Dova Pharmaceuticals | $18.78 | 2019 | |
| Array Biopharma INC | $17.37 | 2023 | Lorbrena, Xalkori, Mektovi |
| Rigel Pharmaceuticals, INC. | $12.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Keaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.